Makoto Akiyama*†, Yoshihiro Sowa*, Tomoyuki Taniguchi*, Motoki Watanabe*, Shingo Yogosawa‡, Jo Kitawaki†,Toshiyuki Sakai*
Oncology Research, Vol.25, No.8, pp. 1245-1252, 2017, DOI:10.3727/096504017X14850164661097
Abstract Ovarian cancer is the most lethal disease among gynecological malignancies. More effective therapy is
required to counter high recurrence rates and chemotherapy resistance. We investigated the efficacy and
molecular mechanisms of three combined treatments (TCTs)—a novel histone deacetylase (HDAC) inhibitor OBP-801/YM753, 5-fluorouracil (5-FU), and paclitaxel (PTX)—in human ovarian cancer SKOV-3 and
OVCAR-3 cells. The inhibition of cell growth was stronger with TCTs than with each single agent and with
two combined treatments. The TCTs significantly induce G2 phase arrest in both cell lines. We then analyzed
the molecular mechanisms and found that the TCTs increased the More >
Login
Register
